AstraZeneca buys biotech firm

Article Abstract:

AstraZeneca PLC of the United Kingdom has acquired its partner Cambridge Antibody Technology Group PLC also of the United Kingdom. Share price offer is 13.20 Pounds ($25.01) that values the biotechnology company at approximately 702 million Pounds. The acquisition is valued at 567 million Pounds excluding the AstraZeneca PLC stake of 19.2 percent.

United Kingdom, AstraZeneca PLC, AZN, Cambridge Antibody Technology Group PLC, Company overview

---

ICOS accepts Lilly's sweetened takeover offer

Article Abstract:

Eli Lilly and Co. of the United State is to acquire ICOS Corp. also of the United States for $2.3 billion or $34 per share. ICOS Corp. and Eli Lilly and Co. through a joint venture are marketing the erectile-dysfunction drug Cialis. Projected sales for the drug are $965 million in 2006.

Eli Lilly and Co., LLY, ICOS Corp., ICOS, Financial report

---

Teva Agrees to buy CoGenesys, gaining foothold in biologics

Article Abstract:

Israel's Teva Pharmaceutical Industries Ltd. has purchased US-based CoGenesys Inc., a spinoff of biotechnology firm Human Genome Sciences Inc. The $400 mil cash deal gives Teva, which focuses on generic drug development, an entry into the biologic therapies market.

Parent-to-subsidiary activities, Subsidiary-to-parent activities, Israel, Human Genome Sciences Inc., HGSI, Subsidiaries, divisions and units, Teva Pharmaceutical Industries Ltd.

Similar abstracts:

• Abstracts: AstraZeneca hopes purchase breaks new-product slump: MedImmune offers access to vaccines, biological drugs. Two deals for Europe's drug makers
• Abstracts: Telefonica's profit jumps 40%. Telefonica profit jumps 39% on gain from Endemol sale. Telefonica shows 1.1% profit gain
• Abstracts: Gazprom, Rosneft each pursue deal to acquire Sibneft. Rosneft profit falls 55%
• Abstracts: LSE rebuffs offer by Nasdaq valuing firm at $5.1 billion. Euronext creator reaches for new deal. Euronext, NYSE take merger talk to the next level

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.